AQST (Aquestive Therapeutics) חוב לטווח קצר להון

Aquestive Therapeutics specializes in creating innovative drug delivery systems, yet faces threats of underfunding and regulatory barriers. The business relies on unique soluble films, expanding their application from epilepsy therapy to allergy relief. This chart demonstrates the 0.00 metric, while the company actively implements its developments through strategic alliances to improve treatment efficacy.

To minimize fundamental risks, investors select low-leverage assets where the ratio of liabilities due within one year to equity confirms liquidity. This calculation reveals a company's dependence on short-term borrowing, which is critical for Aquestive Therapeutics (AQST) when paying external CRO partners; therefore, the short-term debt-to-equity chart serves as an indicator of financial stability in the face of potential volatility.